Valuation : Scholar Rock Holding Corporation

Market Cap 6.74B 5.8B 5.45B 4.98B 9.31B 637B 9.34B 64.62B 24.98B 326B 25.31B 24.75B 1,040B P/E 2026 *
-17x
P/E 2027 * -21.5x
Enterprise Value 6.42B 5.52B 5.19B 4.74B 8.87B 607B 8.9B 61.58B 23.8B 311B 24.11B 23.59B 991B EV / Sales 2026 *
1,130x
EV / Sales 2027 * 43.3x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week-2.59%
Current month-2.59%
1 month+4.55%
3 months+24.90%
6 months+22.17%
Current year+25.61%
1 week 55
Extreme 55
58.1
1 month 50.69
Extreme 50.69
61.76
Current year 38.75
Extreme 38.75
61.76
1 year 27.07
Extreme 27.07
61.76
3 years 5.94
Extreme 5.94
61.76
5 years 4.32
Extreme 4.325
61.76
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Tech/Sci/R&D Officer 51 2022-08-31
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Sell

Director

-2,544 0.0022%
7/1/26 Sell

Director

-5,446 0.0047%
7/1/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-2.59%+76.15%+783.87% 6.74B
-0.38%-0.99%+42.69%+100.85% 67.98B
-2.71%-0.71%+35.89%+81.43% 64.94B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
-0.45%-2.47%+23.81%+13.02% 25.74B
-1.11%+0.90%+22.24%-18.50% 20.09B
+1.15%-5.02%+219.82%+379.02% 17.16B
-1.55%-1.43%-8.30%+518.18% 14.92B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.58%+0.46%+44.74%+238.75% 28.58B
Weighted average by Cap. -0.82%+0.35%+37.47%+154.19%

Financials

2026 *2027 *
Net sales 5.68M 4.89M 4.6M 4.2M 7.85M 538M 7.87M 54.51M 21.07M 275M 21.35M 20.88M 877M 146M 126M 118M 108M 202M 13.82B 202M 1.4B 542M 7.08B 549M 537M 22.54B
Net income -425M -366M -344M -314M -587M -40.23B -589M -4.08B -1.58B -20.6B -1.6B -1.56B -65.62B -364M -313M -294M -269M -502M -34.41B -504M -3.49B -1.35B -17.62B -1.37B -1.34B -56.13B
Net Debt -317M -273M -257M -234M -438M -29.99B -439M -3.04B -1.18B -15.36B -1.19B -1.16B -48.93B -405M -348M -328M -299M -559M -38.29B -561M -3.88B -1.5B -19.61B -1.52B -1.49B -62.46B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-09-04 $55.33 -1.09% 658,048
26-09-03 $55.94 -0.29% 803,486
26-09-02 $56.10 +0.38% 1,065,938
26-09-01 $55.89 -1.60% 763,186
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
55.33USD
Average target price
60.75USD
Spread / Average Target
+9.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!